v3.23.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 3,829,482 $ 3,147,702
Unbilled receivable 107,578 276,821
Right-of-use asset 10,866 27,165
Prepaid expenses and other current assets 1,907,147 1,847,481
Total current assets 5,855,073 5,299,169
Other assets 502,550 585,883
Total assets 6,357,623 5,885,052
Current liabilities:    
Accounts payable 1,274,629 2,943,791
Accrued expenses and other liabilities 785,827 2,226,494
Lease liability 10,926 27,315
Notes payable and accrued interest 445,738 4,266,610
Total current liabilities 2,517,120 9,464,210
Long-term liabilities:    
Notes payable, net of current portion 140,148
Liability classified warrants 47,696 310,346
Total long-term liabilities 47,696 450,494
Total liabilities 2,564,816 9,914,704
Stockholders’ equity deficit    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2023 and December 31, 2022; 2,669,873 and 534,571 shares issued at June 30, 2023 and December 31, 2022, respectively; 2,669,792 and 534,490 shares outstanding at June 30, 2023 and December 31, 2022, respectively 267 53
Additional paid-in capital 119,481,957 107,216,566
Accumulated deficit (115,363,208) (110,931,063)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 4,119,016 (3,714,444)
Noncontrolling interests in stockholders’ equity (deficit) (326,209) (315,208)
Total stockholders’ equity (deficit) 3,792,807 (4,029,652)
Total liabilities and stockholders’ equity (deficit) $ 6,357,623 $ 5,885,052

Source

PDF HTML
ZIP XLS XBRL